Theranostics

Theranostics is a fully open access, peer-reviewed multidisciplinary journal published by Ivyspring International Publisher, established in 2011 and dedicated to integrating molecular imaging and molecular therapy, with a 2025 Journal Impact Factor of 14.9（Theranostics）是由（Ivyspring International Publisher）出版的完全开放获取同行评审多学科期刊，2011 年创刊，致力于整合分子影像与分子治疗，2025 年影响因子为 14.9。

Scope

• It provides a forum for exchanging clinical and scientific information for the diagnostic and therapeutic molecular and nano medicine community该刊为诊断与治疗分子及纳米医学界提供临床与科学信息交流的平台。
• It publishes innovative and original research reflecting in vitro diagnostics and prognostics, in vivo molecular imaging, and molecular therapeutics该刊发表反映体外诊断与预后、体内分子影像以及分子治疗学的创新性原创研究。^[1]
• Its coverage extends to image-guided therapy, biosensors, nanobiosensors, bioelectronics, systems biology, and translational medicine其覆盖范围延伸至影像引导治疗、生物传感器、纳米生物传感器、生物电子学、系统生物学与转化医学。^[2]
• It addresses point-of-care and personalized medicine and encourages biomedical research applicable to future theranostic applications该刊关注即时检验与个性化医疗，并鼓励可应用于未来诊疗一体化的生物医学研究。
• In addition to primary research, it publishes reviews, news, and commentary bridging the laboratory, the clinic, and the biotechnology industry除原创研究外，该刊还发表综述、新闻与评论，以弥合实验室、临床与生物技术产业之间的鸿沟。
• Papers in the journal are rigorously peer-reviewed该刊论文均经严格的同行评审。

History

• It was established in 2011 by Ivyspring International Publisher as the first journal devoted to the emerging field of theranostics该刊于 2011 年由（Ivyspring International Publisher）创办，是首个专注于诊疗一体化这一新兴领域的期刊。^[3]
• Its founding Editor-in-Chief Xiaoyuan Chen introduced the journal on 8 January 2011 in an editorial其创刊主编（Xiaoyuan Chen）于 2011 年 1 月 8 日以一篇社论介绍该刊。
• It has been published under an open access model from the outset, with all papers freely and immediately available without access barriers该刊自创刊起即采用开放获取模式，所有论文均免费即时获取、无访问障碍。
• Articles published from 10 June 2019 carry a Creative Commons Attribution 4.0 licence, while earlier articles used CC BY-NC 4.0自 2019 年 6 月 10 日起发表的文章采用（Creative Commons Attribution 4.0）许可，更早的文章采用（CC BY-NC 4.0）许可。
• Its 2025 Journal Impact Factor is 14.9, placing it 6th among 191 journals in Medicine, Research and Experimental其 2025 年影响因子为 14.9，在医学研究与实验类别的 191 种期刊中位列第 6。
• The journal appears online only and is indexed in Science Citation Index Expanded, PubMed/MEDLINE, and PubMed Central该刊仅在线出版，被（Science Citation Index Expanded）、（PubMed/MEDLINE）与（PubMed Central）收录。

Editors

• Its founding Editor-in-Chief is Xiaoyuan Chen, now based at Shandong Cancer Hospital and Institute in China其创刊主编为（Xiaoyuan Chen），现任职于中国（Shandong Cancer Hospital and Institute）。
• The Editorial Advisory Board includes Rahmi Oklu of the Mayo Clinic in the United States编辑顾问委员会包括美国（Mayo Clinic）的（Rahmi Oklu）。
• It includes Angela Casini of the Technical University of Munich and Twan Lammers of RWTH Aachen University in Germany还包括德国（Technical University of Munich）的（Angela Casini）与（RWTH Aachen University）的（Twan Lammers）。
• Kostas Kostarelos of the University of Manchester and David Peter Cormode of the University of Pennsylvania also serve（University of Manchester）的（Kostas Kostarelos）与（University of Pennsylvania）的（David Peter Cormode）也在其中。
• Other members include Hyung-Jun Im of Seoul National University and Jingjing Zhang of the National University of Singapore其他成员包括（Seoul National University）的（Hyung-Jun Im）与（National University of Singapore）的（Jingjing Zhang）。
• The Managing Editor is Junjie Cheng执行编辑为（Junjie Cheng）。